The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident ...
Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for its NxTAG® Respiratory Pathogen Panel. The Panel detects 21 clinically-relevant viral and bacterial ...
SANTA FE SPRINGS, Calif., May 04, 2026--(BUSINESS WIRE)--Applied BioCode, a leader in multiplex molecular diagnostic solutions, today announced a significant enhancement to its BioCode ® Respiratory ...
Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for its NxTAG® Respiratory Pathogen Panel that detects 20 clinically relevant viral and bacterial respiratory ...
CORALVILLE, Iowa--(BUSINESS WIRE)--To meet customer demand for a multiplexed, multiple respiratory disease target panel that provides comprehensive genome coverage, Integrated DNA Technologies (IDT) ...
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in innovative molecular diagnostic solutions, announced today the submission of a new nucleic acid extraction claim for the ...
A 45-reference UltraGene range, new respiratory panels and high-multiplex prototypes strengthen ABL Diagnostics ...
Routine use of rapid respiratory virus testing in the emergency department (ED) appears to show limited benefit among patients with signs and symptoms of acute respiratory infection (ARI), according ...
Applied BioCode, a leader in multiplex molecular diagnostic solutions, today announced a significant enhancement to its BioCode® Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results